Corporate Governance | Regeneron Pharmaceuticals Inc.

Date	Name	Title	Filing	Type	Shares Traded	Price	Total Held
Feb 07, 2012	GOLDBERG MURRAY A SVP Finance and Admin CFO Trea Trans History: 645	SVP Finance and Admin CFO Trea	Form 4	Open market or private sale of non-derivative or derivative security	13,265	$99.67	91,346
May 21, 2020	VAGELOS P ROY Director, Chairman of the Board Trans History: 742	Director, Chairman of the Board	Form 4	Open market or private sale of non-derivative or derivative security	13,268	$564.62	374,219
Feb 17, 2016	Sanofi Ten Percent Owner Trans History: 555	Ten Percent Owner	Form 4	Open market or private purchase of non-derivative or derivative security	13,288	$395.32	23,338,947
Nov 05, 2015	STAHL NEIL EVP Research and Development Trans History: 660	EVP Research and Development	Form 4	Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3	13,312	$567.63	64,130
Sep 18, 2013	VAGELOS P ROY Director, Chairman of the Board Trans History: 742	Director, Chairman of the Board	Form 4	Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3	13,346	$304.38	364,913
Dec 15, 2016	SCHLEIFER LEONARD S Director, President & CEO Trans History: 427	Director, President & CEO	Form 4	Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3	13,365	$380.09	279,441
May 13, 2013	STAHL NEIL SVP Research and Development S Trans History: 660	SVP Research and Development S	Form 4	Open market or private sale of non-derivative or derivative security	13,378	$276.71	58,648
May 06, 2013	Van Plew Daniel P SVP & General Mgr Industrial O Trans History: 359	SVP & General Mgr Industrial O	Form 4	Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3	13,450	$260.44	24,461
May 07, 2013	YANCOPOULOS GEORGE Director, President Regeneron Laboratori Trans History: 673	Director, President Regeneron Laboratori	Form 4	Open market or private sale of non-derivative or derivative security	13,457	$261.66	1,192,938
Dec 04, 2023	MURPHY ANDREW J EVP Research Trans History: 222	EVP Research	Form 4	Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3	13,464	$813.58	65,957

* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.

Investors & Media